This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



alogliptin/pioglitazone (Incresync®)


Reference No. 1272

Publication date:
27/02/2014


Appraisal information

alogliptin/pioglitazone (Incresync®) 12.5 mg/45 mg film-coated tablet
alogliptin/pioglitazone (Incresync®) 12.5 mg/30 mg film-coated tablet
alogliptin/pioglitazone (Incresync®) 25 mg/45 mg film-coated tablet
alogliptin/pioglitazone (Incresync®) 25 mg/30 mg film-coated tablet


Company: Takeda UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, alogliptin/pioglitazone (Incresync®) cannot be endorsed for use within NHS Wales for second or third line treatment in adult patients aged 18 years and older with type 2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance; and in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
Statement of Advice (SOA)
Download